View
14
Download
0
Category
Preview:
Citation preview
焦
點
人
物
台大藥刊
�
主任的話
‧李水盛主任
今年上半年對本系而言大有「多事」之秋之慨。從1月14日之陳春雄老師榮退,繼
以3月25日舉辦孫教授之追思紀念會,4月18日許照惠系友會見李校長而簽署建藥學館
承諾書事件,而隨之而來之藥學系改制計畫-擬四年制、六年制雙軌並行,藥學館籌建
規劃,與新成立之分子醫藥學程師資之遴聘,其間穿插著2月1日第41屆系友郭錦樺及
8月1日本系第一位博士班畢業生沈雅敬老師之到聘、高純琇老師借調財團法人醫藥品
查驗中心、第10屆系友之畢業四十週年與第20屆系友畢業三十週年返校活動(4月29
日),林林總總,不一而足。
這些事情,有些代表著系的薪火相傳已階段性完成,即第一代之師資已由第二
代以後之專才接棒。值得一書的事,林慧玲老師自8月1日起擔任藥劑部主任,開啟由
臨床藥學專業師資擔任斯職之首例,爾後想必有一番新氣象。
自許系友承諾捐款蓋藥學大樓之後,9月9日在其積極運籌下成立臺大藥物科技
發展基金會之雛型,預計在年底前能正式運作,以彙集並整合系友之力量,全力促成
臺大藥學之夢—具充分發展空間之世界一流藥學院。此臺大藥學永續經營規劃及系友
之熱心參與,已被校長譽為臺大前所未有之典範。期盼在眾志成河之前提下,群策群
力,早日圓夢。
49期���
焦
點
人
物
�
2006年傑出系友得獎人-方森茂校友
‧Sen-Maw Fang, Ph.D.
Dr.Sen-MawFanggraduatedfromtheSchoolofPharmacy,National
TaiwanUniversityin1959(第三屆)andwentontoreceiveM.S.andPh.D.
degreesfromtheCollegeofPharmacy,UniversityofIllinoisin1968.Hethen
post-doctoredattheBenMayCancerResearchInstitute,UniversityofChicago
andworkedonareasofandrogenreceptorsinratprostate.Theworkculminated
intheidentificationoftestosteroneconversiontodihydrotestosterone(DHT)
inthenucleiofprostaticcellsby5-alphareductase.DHTwasfoundtobethe
activeandrogeninprostateandwasimplicatedinprostatichypertrophyand
prostatecancer.
In1971,he accepted a teaching job at both theDepartmentofPharmacyand theDepartmentof
Pharmacologyat theCollegeofPharmacy,UniversityofUtah. Hecontinuedtoworkonandrogenreceptors
inhumanprostatethroughfundingbyNationalCancerInstitute.HealsoreceivedNICHDfundingtoworkon
thepharmacokineticsofestrogenandprogestinsintheuterinehornofratsafterIUDadministration.Through
agroupproject,healsostudiedthepharmacokineticsofnorethindronereleasefromapolyglutamatepolymer
deviceafter i.m. injection. Healsoreceivedgrants toworkon thebioavailabilityandpharmacokineticsof
minerals inrat intestinesbeforeandafter themineralswerechelatedwithvariousligands Healsoservedas
consultantinchelatedmineralsforinternalaswellascosmeticapplications.DuringhistenureintheUniversity
ofUtah,hetaughtbothundergraduateandgraduatecoursesinbiopharmaceuticsandpharmacokineticsinthe
CollegeofPharmacyandalsoparticipatedingrouplecturestoMasterdegreestudentsintheCollegeofNursing
andtheCollegeofMedicine.
Dr.Fangleft theacademyin1985topursuefull timehisentrepreneurship. HeestablishedAMTLabs
inSaltLakeCity,whichisarawmaterialsupplier tomostlynutritionalfoodsupplementindustries. Besides
chemicalsynthesisofchelatedminerals, thecompanyalsomakeotheringredientswhichtotalmorethan300
items.AMTalsoprovidespecialformulationssuchassustainedreleasetablets,directlycompressablegranules,
effervescentpowders,energydrinks,highsolubilitymineralproduct,etc.Thecompanyhasproductsmarketed
allovertheworld.
He isnowsemi-retiredandspendhis timemostlyonerhu (ChineseTraditionalOrchestra), singing
(baritonesoloistinthechorus)andtennis.Hehasestablishedafoundationtohelpvariouscharityactivitiesin
SaltLakeCityandotherareas.Hismostpleasurenowistohorsearoundwithhisthreeyounggrandkids.
焦
點
人
物
台大藥刊
�
Dr.JinnWuobtainedhisB.S.inPharmacyandaM.S.inPharmaceutical
ChemistryfromtheSchoolofPharmacy,NationalTaiwanUniversityin1971
(第15屆)and1975 (under the supervisionofProfessorChung-Hsiung
Chen),respectively.HeearnedaPh.D.degreeinNaturalProductsChemistry
andMedicinalChemistryfromtheCollegeofPharmacy(underthesupervision
ofProfessorsJackL.BealandRaymondDoskotch),TheOhioStateUniversity
in1979.Hewasapostdoctoralresea rchassociateintheareasofBiomedical
MassSpectrometryanddrugmetabolismattheDepartmentofPharmacology,
CollegeofMedicine,TheOhioStateUniversity from1979 -1980. Dr.
Wu joinedFMCCorporation inPrinceton,NewJersey in1980andmade
numerouscontributionsinnewproductresearchanddevelopmentinmetabolism,bioanalyticalchemistry,and
environmentalchemistry.
Dr.JinnWuestablishedXenoBioticLaboratories,Inc.(XBL)in1987inPlainsboro,NewJersey. This
companyisconsideredasoneofthetopGLPcontractresearchlaboratoriesintheUSAwithhighreputationin
invitro/invivodrugmetabolism,pharmacokinetics,metaboliteprofiling,metaboliteidentificationandclinical
bioanalysis.
Dr.WuisamemberoftheAmericanChemicalSociety(ACS),theAmericanSocietyofPharmacognosy
(ASP), the InternationalSociety for theStudyofXenobiotics (ISSX),AmericanChinesePharmaceutical
Association (ACPA),Sino-AmericanPharmaceuticalAssociation (SAPA) and amemberofAmerican
AssociationofPharmaceuticalScientists(AAPS).Hehaspublished48scientificpapers.
Dr.Wuhasbeenveryactiveinpublicservices.HewastheTeamManagerforNTUCollegeofMedicine
SoccerTeam(1968-71)andwonNationalCollegesofMedicineChampionshipin1970. Hehasservedasa
consultantforNIH-NCIfornationalresearchgrantproposalreview,wasamemberoftheBoardofDirectorsat
ArdentPharmaceuticals,Inc.,ViceChairmanandamemberoftheBoardofDirectorsforMonteJadeScience&
TechnologyAssociation(EastCoast),PresidentofACPAandNationalTaiwanUniversitySchoolofPharmacy
AlumniAssociation–NorthAmerica(NTUSPAA-NA)2001-2003.HewastherecipientofTheJackL.Beal
PostbaccalaureateAward,CollegeofPharmacy,TheOhioStateUniversity,in1994.
2006年傑出系友得獎人-吳 晉校友
‧Jinn Wu (吳晉), Ph.D.
49期���
焦
點
人
物
�
Dr.Mei-LingChen isAssociateDirector,OfficeofPharmaceutical
Science,Center forDrugEvaluation andResearch (CDER),U.S.Food
andDrugAdministration (FDA). The superofficeprovidesoversightof
scientificreviews,regulatorypoliciesandresearchactivitiesfortheOfficeof
BiotechnologyProducts,OfficeofGenericDrugs,OfficeofNewDrugQuality
Assessment,andOfficeofTestingandResearch. Over theyears,Dr.Chen
hasservedasanadvisertotheBureauofPharmaceuticalAffairs,Department
ofHealth,ExecutiveYuan,Taiwan,RepublicofChina. Since2001,shehas
beenrecognizedasaFellowoftheAmericanAssociationofPharmaceutical
Scientists (AAPS),aprofessionalscientificsocietyofmore than12,000membersfromacademia, industry,
governmentandotherresearchinstitutesworldwide.SheisontheEditorialBoardofClinicalPharmacokinetics,
aco-editorof thebookentitled“ClinicalTrialsofDrugsandBiopharmaceuticals",a refereeofseveral
prestigiousscientificjournals,andtheauthororco-authorofnumerousreviewarticles,bookchapters,research
papersandabstractsinthefieldofclinicalpharmacologyandbiopharmaceutics.
Dr.Chenwasborn inTaiwanandreceivedherB.S. inPharmacyfromtheNationalTaiwanUniversity
(第18屆). SheearnedherPh.D.inPharmacokineticsandBiopharmaceuticsfromtheUniversityofIllinois
atChicagoin1982. Followingatwo-yearpostdoctoral training,Dr.ChenjoinedtheFDAin1984. Shewas
honoredasaregulatoryexpert in1990andadvancedtoChief,PharmacokineticsEvaluationBranch,Division
ofBiopharmaceutics,OfficeofResearchResourcesin1994. Dr.ChenwaspromotedtoDirector,Divisionof
PharmaceuticalEvaluationII,OfficeofClinicalPharmacologyandBiopharmaceuticsin1995,andAssociate
Director,OfficeofPharmaceuticalSciencein2000.
WhileintheFDA,Dr.ChenhasbeenappointedasCo-ChairoftheComplexDrugSubstancesCoordinating
Committee,andTopicLeadoftheBiopharmaceuticsCoordinatingCommitteeinCDER.Shehasalsoserved
aschairpersonorco-chairpersonofseveralworkinggroupsonhighlycontroversialand/orimportantscientific
issues.SheisinstrumentalinthedevelopmentofmanyFDAguidanceandpolicydocumentsforpharmaceutical
industryandFDAstaff,inparticular,onthetopicsrelatedtobioavailabilityandbioequivalence.Dr.Chenhas
receivednumerousmeritawardsfromtheFDA.
Asascientificandregulatoryexpert,Dr.Chenhasfrequentlybeenrequestedasaspeakerormoderator
atnationalandinternationalmeetings.From2000to2005,shewaselectedtoserveontheU.S.Pharmacopeia
(USP)ExpertCommittee-BioavailabilityandNutrientAbsorption. Additionally,shewasontheUSPExpert
Panel-ActiveComplexesfrom2003to2004andontheUSPAdvisoryPaneltotheInternationalHealthExpert
Committeein2005.
2006年傑出系友得獎人-陳美玲校友
‧Mei-Ling Chen, Ph.D.
焦
點
人
物
台大藥刊
�
2006年傑出系友得獎人-黃秀美校友
‧Amy Huang
AmyHuangisVicePresidentandAreaDirectorofGlaxoSmithKline.She
isresponsibleforallcommercialoperationsofGlaxoSmithKlineinChinaand
HongKong.
MsHuangwasborninTaiwanandearnedherB.S.inPharmacyatNational
Taiwan University(第19屆). From 1997 to 2005, Ms. Huang was the
ManagingDirectorforGlaxoSmithKlineTaiwan.Thisfollowedhertenureasthe
MarketingDirectorforSmithKlineBeechamfrom1993to1997.
Between1982to1993,Ms.HuangheldvariouspositionswithinSmithKline
BeechamPharmaceuticals, includingActingSalesManager,ProductManager,
MedicalandClinicalResearchManager,MarketingManager,andBusinessDevelopmentDirector (Taiwan
&China).Prior to this,Ms.Huangplayedvariousroles fromsales training,product regulatory toproduct
managementforalocalpharmaceuticalcompany,Su-Chiang&Co.Ltd.(ThesoleagentforSK&F)from1976
to1982,aftergraduatingwithadegreeinPharmacyfromtheNationalTaiwanUniversity.
Ms.Huang isanactivememberofmany industryassociations.Shemost recentlyservedasCo-Chair
for thePharmaceuticalCommitteeofEuropeanChamberofCommerceTaipei (ECCT),andChaired the
CommunicationsCommitteeofTaiwan´s InternationalResearch-BasedPharmaceuticalManufacturers
Association(IRPMA).ShewasaBoardmemberof theTaiwanPharmaceuticalMarketing&Management
Association(TPMMA),andaDirector for the IRPMAand theTaiwanProductQualityResearchInstitute
(TPQRI).ShewasamemberofboththeAmericanChamberofCommerceinTaiwanandtheBritishChamberof
CommerceinTaipei.NowsheisoneoftheECRDPACinChina.
Ms.Huangisaninspirational leaderandsuccessfulexecutive. Hernumerousawardsandachievements
includeOutstandingPharmaceuticalManager(Taiwan)andGSK´sInspirationalLeadershipAward(2005).
Since themergerofGlaxoWellcomeandSmithKlineBeechamin2001,shepresidedover recordcountry
performanceduringa turbulentperiodofregulation.Duringher tenureasManagingDirectorofSmithKline
BeechamTaiwan,sheoversawthelaunchesofEngerixB,Tagmet,Augmentin,AvandiaandSeretideetc., the
mostsuccessfulblockbustersinTaiwanPharmaceuticalindustryhistory.
GSKisaworldleadingresearch-basedpharmaceuticalcompanywithapowerfulcombinationofskillsand
resourcesthathelppeoplearoundtheworlddomore,feelbetterandlivelonger.
Recommended